224 related articles for article (PubMed ID: 35058934)
1. CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
Hejazi M; Zhang C; Bennstein SB; Balz V; Reusing SB; Quadflieg M; Hoerster K; Heinrichs S; Hanenberg H; Oberbeck S; Nitsche M; Cramer S; Pfeifer R; Oberoi P; Rühl H; Oldenburg J; Brossart P; Horn PA; Babor F; Wels WS; Fischer JC; Möker N; Uhrberg M
Front Immunol; 2021; 12():798087. PubMed ID: 35058934
[TBL] [Abstract][Full Text] [Related]
2. A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
Vargas-Inchaustegui DA; Demberg T; Robert-Guroff M
Immunology; 2011 Nov; 134(3):326-40. PubMed ID: 21978002
[TBL] [Abstract][Full Text] [Related]
3. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
4. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
[TBL] [Abstract][Full Text] [Related]
5. Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells.
Handgretinger R; Schäfer HJ; Baur F; Frank D; Ottenlinger C; Bühring HJ; Niethammer D
Immunol Lett; 1993 Aug; 37(2-3):223-8. PubMed ID: 7505004
[TBL] [Abstract][Full Text] [Related]
6. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
7. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential.
Lehmann D; Spanholtz J; Sturtzel C; Tordoir M; Schlechta B; Groenewegen D; Hofer E
PLoS One; 2014; 9(1):e87131. PubMed ID: 24498025
[TBL] [Abstract][Full Text] [Related]
8. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
9. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
Front Immunol; 2021; 12():640672. PubMed ID: 34017328
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
[TBL] [Abstract][Full Text] [Related]
12. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia.
Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
Cancer Lett; 2023 Apr; 558():216103. PubMed ID: 36805460
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells.
Lehmann D; Spanholtz J; Osl M; Tordoir M; Lipnik K; Bilban M; Schlechta B; Dolstra H; Hofer E
Stem Cells Dev; 2012 Nov; 21(16):2926-38. PubMed ID: 22571679
[TBL] [Abstract][Full Text] [Related]
14. The biology of human natural killer-cell subsets.
Cooper MA; Fehniger TA; Caligiuri MA
Trends Immunol; 2001 Nov; 22(11):633-40. PubMed ID: 11698225
[TBL] [Abstract][Full Text] [Related]
15. Human NK cells proliferate and die in vivo more rapidly than T cells in healthy young and elderly adults.
Lutz CT; Karapetyan A; Al-Attar A; Shelton BJ; Holt KJ; Tucker JH; Presnell SR
J Immunol; 2011 Apr; 186(8):4590-8. PubMed ID: 21402893
[TBL] [Abstract][Full Text] [Related]
16. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
Marin V; Pizzitola I; Agostoni V; Attianese GM; Finney H; Lawson A; Pule M; Rousseau R; Biondi A; Biagi E
Haematologica; 2010 Dec; 95(12):2144-52. PubMed ID: 20713459
[TBL] [Abstract][Full Text] [Related]
17. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15.
Loubeau M; Ahmad A; Toma E; Menezes J
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):137-45. PubMed ID: 9390564
[TBL] [Abstract][Full Text] [Related]
19. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
20. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
